280 related articles for article (PubMed ID: 23206263)
21. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).
Jongen PJ; Hengstman G; Hupperts R; Schrijver H; Gilhuis J; Vliegen JH; Hoogervorst E; van Huizen M; van Munster E; Samijn J; de Schryver E; Siepman T; Tonk M; Zandbergen E; ten Holter J; van der Kruijk R; Borm G
BMC Neurol; 2011 Mar; 11():40. PubMed ID: 21450086
[TBL] [Abstract][Full Text] [Related]
22. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.
Menzin J; Caon C; Nichols C; White LA; Friedman M; Pill MW
J Manag Care Pharm; 2013; 19(1 Suppl A):S24-40. PubMed ID: 23383731
[TBL] [Abstract][Full Text] [Related]
23. Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.
Cascione M; Tenenbaum N; Wendt J; Meng X; Schofield L; Cree BAC;
Mult Scler Relat Disord; 2018 Oct; 25():50-56. PubMed ID: 30036854
[TBL] [Abstract][Full Text] [Related]
24. Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with Schizophrenia.
Shafrin J; Schwartz TT; Lakdawalla DN; Forma FM
J Manag Care Spec Pharm; 2016 Nov; 22(11):1285-1291. PubMed ID: 27783545
[TBL] [Abstract][Full Text] [Related]
25. Does a One-Size-Fits-All Cost-Sharing Approach Incentivize Appropriate Medication Use? A Roundtable on the Fairness and Ethics Associated with Variable Cost Sharing.
Graff JS; Shih C; Barker T; Dieguez G; Larson C; Sherman H; Dubois RW
J Manag Care Spec Pharm; 2017 Jun; 23(6):621-627. PubMed ID: 28530519
[TBL] [Abstract][Full Text] [Related]
26. Emerging oral drugs for relapsing-remitting multiple sclerosis.
Gasperini C; Ruggieri S
Expert Opin Emerg Drugs; 2011 Dec; 16(4):697-712. PubMed ID: 22148963
[TBL] [Abstract][Full Text] [Related]
27. Telemedicine for the Medicare population: pediatric, obstetric, and clinician-indirect home interventions.
Hersh WR; Wallace JA; Patterson PK; Shapiro SE; Kraemer DF; Eilers GM; Chan BK; Greenlick MR; Helfand M
Evid Rep Technol Assess (Summ); 2001 Aug; (24 Suppl):1-32. PubMed ID: 11569328
[TBL] [Abstract][Full Text] [Related]
28. Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit.
Carroll WM
Mult Scler; 2009 Aug; 15(8):951-8. PubMed ID: 19465446
[TBL] [Abstract][Full Text] [Related]
29. Multiple sclerosis: current treatment algorithms.
Río J; Comabella M; Montalban X
Curr Opin Neurol; 2011 Jun; 24(3):230-7. PubMed ID: 21499098
[TBL] [Abstract][Full Text] [Related]
30. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
31. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
32. Will the newer oral MS agents be welcomed by managed care organizations?
Lipsy RJ
Am J Manag Care; 2010 Sep; 16(8 Suppl):S227-33. PubMed ID: 20873947
[TBL] [Abstract][Full Text] [Related]
33. Emerging oral agents for multiple sclerosis.
Fox EJ
Am J Manag Care; 2010 Sep; 16(8 Suppl):S219-26. PubMed ID: 20873946
[TBL] [Abstract][Full Text] [Related]
34. Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers.
Nichol MB; Knight TK; Epstein J; Honda DH; Tretiak R
J Manag Care Pharm; 2007 May; 13(4):360-71. PubMed ID: 17506602
[TBL] [Abstract][Full Text] [Related]
35. New and emerging disease modifying therapies for multiple sclerosis.
Saidha S; Eckstein C; Calabresi PA
Ann N Y Acad Sci; 2012 Jan; 1247():117-37. PubMed ID: 22224673
[TBL] [Abstract][Full Text] [Related]
36. Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs.
Hyland M; Rudick RA
Curr Opin Neurol; 2011 Jun; 24(3):255-61. PubMed ID: 21455068
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
J Clin Neurosci; 2014 Nov; 21(11):1835-46. PubMed ID: 24993135
[TBL] [Abstract][Full Text] [Related]
38. Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians.
Miller RM; Happe LE; Meyer KL; Spear RJ
J Manag Care Pharm; 2012; 18(1):54-62. PubMed ID: 22235955
[TBL] [Abstract][Full Text] [Related]
39. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report.
Fry RN; Avey SG; Sullivan SD
Value Health; 2003; 6(5):505-21. PubMed ID: 14627057
[TBL] [Abstract][Full Text] [Related]
40. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
English C; Aloi JJ
Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
